Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Hawkins, A. Vine, J. Willis, B. Frueh, R. Kurtz, S. Elner, M. Johnson, S. Sneed, J. Hayman, A. Lichter, C. Mcginn, J. Robertson, S. Schoeppel, R. Haken, A. Thompson, K. Meyer, C. Mártonyi, S. Stanley, V. Elner, M. Kincaid, R. Wolter, P. Sternberg, J. Brown, T. Aaberg, A. Capone, T. Wojno, Jennifer Lim, J. Keller, J. Landry, I. Crocker, J. McLaren, C. Aguilera, E. Butker, K. Klee, D. Strongosky, D. Gibbs, L. Curtis, A. Fremstad, R. Waldron, A. Ward, J. Gilman, R. Myles, R. Swords, H. Grossniklaus, F. Calhoun, W. Campbell, W. Jarrett, W. Hagler, R. Halpern, N. Jones, F. Schwaibold, K. Wynn, P. Mondalek, G. Degenhardt, E. Hulsey, D. Lee, J. Aaron, D. Bolerjak, S. Mccart, G. McCoy, K. Thompson, B. Baxter, B. Robinson, K. Wilson, A. Schachat, W. Doll, E. Greenberg, M. Alexander, C. Sackett, M. Goldberg, L. Hammer, N. Iliff, D. Lee, M. Chun, J. Jackson, J. Iannito, W. Lam, L. Pollack, C. Dibernardo, D. Cain, D. Emmert, T. George, Z. Zakov, T. Rice, M. Hartnett, S. Lichterman, K. Dempsey, D. Preseren, J. Niffenegger, M. Novak, S. Pendergast, L. Singermann, D. Weidenthal, H. Zegarra, J. Antoszyk, D. Shina, K. Pillai, D. Knight, K. Coreno (1998)
The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10.American journal of ophthalmology, 125 6
D. Albert (1997)
The ocular melanoma story. LIII Edward Jackson Memorial Lecture: Part II.American journal of ophthalmology, 123 6
B. Hawkins, A. Vine, J. Willis, B. Frueh, K. Itani, R. Kurtz, S. Sneed, J. Hayman, C. Mcginn, R. Diaz, A. Lichter, J. Robertson, S. Schoeppel, R. Haken, A. Thompson, K. Meyer, S. Stanley, C. Mártonyi, V. Elner, M. Kincaid, R. Wolter, P. Sternberg, T. Meredith, J. Brown, Jr Aaberg, S. Aaberg, T. Wojno, J. Keller, J. Landry, I. Crocker, J. McLaren, C. Aguilera, E. Butker, K. Klee, D. Strongosky, D. Gibbs, L. Curtis, A. Fremstad, R. Waldron, A. Ward, J. Gilman, R. Myles, C. Snipes, R. Swords, H. Grossniklaus, J. Calhoun, W. Campbell, J. Frank, W. Jarrett, R. Halpern, W. Hagler, N. Jones, F. Schwaibold, M. Jones, P. Mondalek, K. Wynn, G. Degenhardt, A. Muncey, J. Aaron, D. Bolerjack, C. Cooper, E. Hulsey, L. Kailey, D. Lee, S. Mccart, G. McCoy, M. Clark, B. Baxter, B. Robinson, K. Thompson, K. Wilson, A. Schachat, J. Doll, E. Greenberg, M. Hartnett, M. Alexander, S. Kaiser, C. Sackett, N. Iliff, D. Lee, J. Jackson, J. Ianitto, W. Lam, L. Pollack, C. Dibernardo, D. Cain, D. Emmert, T. George, Z. Zakov, T. Rice, K. Dempsey, G. Daley, D. Preseren, S. Pendergast, H. Zegarra, D. Shina, N. Began, K. Pillai, K. DuBois (2001)
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17.Archives of ophthalmology, 119 7
Ian Mclean, W. Foster (1978)
Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells.British Journal of Ophthalmology, 62
A. Schachat (2002)
THE COMS RANDOMIZED TRIAL OF IODINE 125 BRACHYTHERAPY FOR CHOROIDAL MELANOMA, III: INITIAL MORTALITY FINDINGS COMS REPORT NO. 18Evidence-based Eye Care, 3
L. Zimmerman, Ian LEAN (1979)
An Evaluation of Enucleation in the Management of Uveal MelanomasInternational Ophthalmology Clinics, 20
EDITORIAL The COMS Outcomes for Medium-Sized Choroidal Melanoma HOROIDAL MELANOMA is the most common tality Coding Committee, which carefully assessed the primary ocular malignancy, with some cause of death in each case to judge whether or not this 1500 new cases reported yearly in the was related to the underlying choroidal melanoma. United States. These tumors are both sight- Initial mortality findings in the COMS trial for me- C and life-threatening, with approximately dium-sized choroidal melanomas are reported in this is- a 10% to 30% five-year mortality rate owing to systemic me- sue of the ARCHIVES. This is a landmark study of long du- tastasis, depending on tumor size. Despite the major mor- ration. Patient accrual ran 11 years, from 1987 to 1998, and bidity and mortality from these tumors, the condition oc- these patients have now been followed up for 2 to 13 years. curs infrequently enough in any single ophthalmic prac- Great credit needs be given to the dedication of our col- tice of considerable size that clinical expertise in the condition leagues who accomplished the study. One must marvel at had been difficult to accumulate in years past. Even the ac- their collective exemplary bedside manner,
JAMA Ophthalmology – American Medical Association
Published: Jul 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.